Vijaya Diagnostic Centre Share Price Analyzed
Vijaya Diagnostic Centre’s stock jumped significantly on Thursday, hitting a new high of ₹1,112.40 on the National Stock Exchange (NSE). This was a 11% increase compared to its previous closing price. This positive movement occurred within a broader market that was experiencing limited gains.
Key Points
- Vijaya Diagnostic’s stock soared 11% to ₹1,112.40 on Thursday.
- The stock reached a peak since September 2025.
- Strong investor interest fuels stock increase.
- Revenue grew 10% year-over-year to ₹202 crore.
- EBITDA margin remained strong at 40.6%.
- Industry expected to grow with healthcare demand.
Vijaya Diagnostic is one of India’s biggest companies that offers a complete solution for health tests, covering both blood tests and imaging services. Investors are noticing this growth, which is driving up the stock price.
During the September quarter of 2025 (Q2FY26), the company’s income increased by 10.2% compared to the same period last year, and by 7.2% compared to the previous quarter. This increase was mainly due to a 8.3% rise in the number of tests conducted.
Despite this revenue increase, the company’s profit after tax only rose by 2.7% to ₹43.28 crore. The company’s operating profit, called EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortization), stayed robust at 40.6%. This shows the company is running efficiently.
The management team reported a positive start to the third quarter of 2025 (Q3FY26), noting an increase in customers visiting its centers and a rise in revenue. A particularly successful new location in Yelahanka, Bengaluru, reached profitability faster than expected, within just two quarters.
CareEdge Ratings believes India’s diagnostic services market will continue to grow quickly – about 12% each year for the next few years, reaching $15-16 billion by 2030. This growth is thanks to more people paying attention to their health, a growing population, and more people having health insurance. However, competition is making it harder for companies to make big profits.
CareEdge Ratings says big diagnostic companies need to focus on doing more tests, running their businesses efficiently, and using new technology like artificial intelligence (AI) and genetic testing to stay profitable. They also predict that larger companies will merge or buy smaller ones, making the industry more powerful.
Even though diagnostic testing makes up less than 10% of the whole healthcare industry in India, it’s incredibly important for finding illnesses early and helping doctors make the best treatment choices. The fact that these tests are affordable makes them even more popular.
Diagnostic testing is a vital part of healthcare, helping doctors quickly understand a patient’s condition and guide treatment.
